Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PGD | P52209 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5198986 | 1.00 | LMNA (0.33) | LMNASMN1; SMN2PGDCYP1A2MAPK1 | |
| SCHEMBL2636857 | 0.90 | SMN1; SMN2 (0.35) | LMNASMN1; SMN2PGDCYP1A2 | |
| SCHEMBL9274693 | 0.85 | PRKCA (0.33) | LMNASMN1; SMN2PGD | |
| SCHEMBL22288952 | 0.85 | PRKCA (0.33) | LMNASMN1; SMN2PGD | |
| SCHEMBL2169684 | 0.85 | LMNA (0.33) | LMNASMN1; SMN2PGD | |
| SCHEMBL5451481 | 0.85 | LMNA (0.33) | LMNASMN1; SMN2PGD | |
| SCHEMBL10860800 | 0.85 | LMNA (0.33) | LMNASMN1; SMN2PGD | |
| SCHEMBL13906594 | 0.84 | LMNA (0.35) | LMNASMN1; SMN2PGD | |
| SCHEMBL5452684 | 0.84 | LMNA (0.32) | LMNASMN1; SMN2PGDTSHR | |
| SCHEMBL13906596 | 0.84 | LMNA (0.35) | LMNASMN1; SMN2PGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237814-A1 | NOVEL RUTHENIUM CARBONYL COMPLEX HAVING TRIDENTATE LIGAND, ITS PRODUCTION METHOD AND USE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-09-29 | — | — | US | disclosed |
| EP-0269236-B1 | PROCESS FOR SYNTHESIS OF A CHIRAL AZETIDINONE | MERCK & CO. INC. (US) | 1991-04-03 | — | — | EP | disclosed |
| EP-0269236-A1 | Process for synthesis of a chiral azetidinone | MERCK & CO. INC. (US) | 1988-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237814-A1 | NOVEL RUTHENIUM CARBONYL COMPLEX HAVING TRIDENTATE LIGAND, ITS PRODUCTION METHOD AND USE | ADH1C, ADH1A, ADH5 | LMNA 4164/4885SMN1; SMN2 4882/4885PGD 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.